Cargando…

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaderbhaï, Courèche, Tharin, Zoé, Ghiringhelli, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406957/ https://www.ncbi.nlm.nih.gov/pubmed/30744168 http://dx.doi.org/10.3390/cancers11020201

Ejemplares similares

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life
por: Dalens, Lorraine, et al.
Publicado: (2022)

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report
por: Tankere, Pierre, et al.
Publicado: (2022)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma
por: Lecuelle, Julie, et al.
Publicado: (2021)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022)

Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer
por: Lee, Dagyeong, et al.
Publicado: (2023)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
por: Goode, Emily F., et al.
Publicado: (2021)

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
por: Dalens, Lorraine, et al.
Publicado: (2023)

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer
por: Ghiringhelli, Francois, et al.
Publicado: (2018)

Utility of exome sequencing in routine care for metastatic colorectal cancer
por: D'Agay, Melchior De Giraud, et al.
Publicado: (2021)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
por: Du, Fenqi, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Frigola, Joan, et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
por: Shen, Luhui, et al.
Publicado: (2023)

Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
por: Gibellini, Lara, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
por: Garmezy, Benjamin, et al.
Publicado: (2022)

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer
por: Gao, Chanchan, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
por: Lapuente-Santana, Óscar, et al.
Publicado: (2021)

Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
por: Ichiki, Yoshinobu, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
por: Basudan, Ahmed M.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c1h0pknpjn2mr9njlrkra97td4